Compare FSI & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSI | INMB |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.7M | 64.7M |
| IPO Year | 2000 | 2018 |
| Metric | FSI | INMB |
|---|---|---|
| Price | $6.03 | $0.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | 12.2K | ★ 343.0K |
| Earning Date | 12-02-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.69% | N/A |
| EPS Growth | N/A | ★ 11.85 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,494,325.00 | $50,000.00 |
| Revenue This Year | $24.09 | N/A |
| Revenue Next Year | $60.56 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 257.14 |
| 52 Week Low | $4.85 | $0.89 |
| 52 Week High | $7.52 | $2.60 |
| Indicator | FSI | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 39.73 | 23.55 |
| Support Level | $5.82 | N/A |
| Resistance Level | $6.11 | $1.52 |
| Average True Range (ATR) | 0.21 | 0.12 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 2.13 | 0.65 |
Flexible Solutions International Inc develops, manufactures, and markets specialty chemicals that slow the evaporation of water. Its business is organized into two segments: Energy and Water Conservation Products and Biodegradable Polymers. It offers a liquid swimming pool blanket under the WATERSAVR brand, which saves energy and water by inhibiting evaporation from the pool surface, and a chemical product called HEATSAV for use in swimming pools and spas to slow water evaporation. The company also manufactures and markets water-soluble chemicals utilizing thermal polyaspartate biopolymers. It generates the majority of its revenues from the export of its products to international markets.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.